Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
Sheila Frame is the vice president of marketing, market access, and patient services at Sandoz.
Transcript:
How do you think policy changes will affect the biosimilar market?
The great thing about the policy environment in the United States today is, finally, people are realizing that the current US system is not sustainable. Biosimilars offer such an obvious opportunity for immediate savingd that not only will help save the system, but also will improve access and certainly improve patient care. So, some of the policies that we're putting forward through the Biosimilars Forum relate to the experience that we've had in Europe and in Canada and in other countries, where you know that if you encourage incentives in the system, physicians and patients will adopt biosimilars much more quickly. We also know that most of the hospitals in the [Medicare] Part B space and in the medical benefits space really are trying to push quality and improve quality. So, quality star ratings in the United States, if these organizations adopt biosimilars quickly, should be given great credit. It's probably the one item that achieves complete bipartisan support in the United States. We've got 5 bills in front of Congress in the Senate right now that will definitely spur and encourage biosimilars. And finally, the balance and the opportunity that biosimilars create, to make space in the system for those important innovations that are coming through that are leading to cures in many of these areas. So, those are the policy areas that we're really advancing now, and I feel very confident and optimistic that we're going to see some movement in this regard this year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.